226 related articles for article (PubMed ID: 25637377)
1. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
[TBL] [Abstract][Full Text] [Related]
2. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
Dougherty DD; Jameson M; Deckersbach T; Loh R; Thompson-Hollands J; Jenike M; Keuthen NJ
Int Clin Psychopharmacol; 2009 Nov; 24(6):306-11. PubMed ID: 19730388
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
5. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH
Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253
[TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
7. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.
Dell'osso B; Mundo E; Marazziti D; Altamura AC
J Psychopharmacol; 2008 Mar; 22(2):210-3. PubMed ID: 18208931
[TBL] [Abstract][Full Text] [Related]
8. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder.
Costa DLDC; Barbosa VS; Requena G; Shavitt RG; Pereira CAB; Diniz JB
J Psychopharmacol; 2017 Oct; 31(10):1312-1322. PubMed ID: 28441896
[TBL] [Abstract][Full Text] [Related]
10. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.
Stein DJ; Hollander E; Anthony DT; Schneier FR; Fallon BA; Liebowitz MR; Klein DF
J Clin Psychiatry; 1992 Aug; 53(8):267-71. PubMed ID: 1386848
[TBL] [Abstract][Full Text] [Related]
12. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment.
Saxena S; Maidment KM; Vapnik T; Golden G; Rishwain T; Rosen RM; Tarlow G; Bystritsky A
J Clin Psychiatry; 2002 Jan; 63(1):21-7. PubMed ID: 11838621
[TBL] [Abstract][Full Text] [Related]
13. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence.
Bent AE; Gousse AE; Hendrix SL; Klutke CG; Monga AK; Yuen CK; Muram D; Yalcin I; Bump RC
Neurourol Urodyn; 2008; 27(3):212-21. PubMed ID: 17580357
[TBL] [Abstract][Full Text] [Related]
15. The use of psychotropic agents for the symptoms of obsessive-compulsive disorder.
Brakoulias V; Starcevic V; Berle D; Milicevic D; Moses K; Hannan A; Sammut P; Martin A
Australas Psychiatry; 2013 Apr; 21(2):117-21. PubMed ID: 23426097
[TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine treatment of obsessive-compulsive disorder.
Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
[TBL] [Abstract][Full Text] [Related]
17. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions.
Rosario-Campos MC; Miguel EC; Quatrano S; Chacon P; Ferrao Y; Findley D; Katsovich L; Scahill L; King RA; Woody SR; Tolin D; Hollander E; Kano Y; Leckman JF
Mol Psychiatry; 2006 May; 11(5):495-504. PubMed ID: 16432526
[TBL] [Abstract][Full Text] [Related]
18. Clinical correlates of social adjustment in patients with obsessive-compulsive disorder.
Rosa AC; Diniz JB; Fossaluza V; Torres AR; Fontenelle LF; De Mathis AS; da Conceição Rosário M; Miguel EC; Shavitt RG
J Psychiatr Res; 2012 Oct; 46(10):1286-92. PubMed ID: 22800713
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
20. [The Yale-Brown Scale: instrument for assessing the severity of obsessive-compulsive disorders].
Kiejna A; Grzesiak M; Małyszczak K
Psychiatr Pol; 1998; 32(1):69-76. PubMed ID: 9594585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
